This research report “Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017” provides an overview of the genetic disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Becker and Duchenne Muscular Dystrophy (BMD and DMD) and features dormant and discontinued projects. Both indications covered are inherited muscular dystrophies, a group of genetic, degenerative diseases primarily affecting voluntary muscles.
Complete research report of 79 pages including 68 List of Tables and 21 List of Figures is available at https://www.marketinsightsreports.com/reports/051811077/genetic-disorder-cluster-muscular-dystrophy-drug-development-pipeline-review-2017
BMD, the first type of muscular dystrophy, leads to symptoms include pain and sensation, difficulty with running, hopping, and jumping, toe walking, breathing problems, cognitive problems and frequent falls. There are a total of 6 products in development for this indication, by 6 seperate companies; the companies operating in this pipeline space are all small pharmaceutical enterprises, and consist of Armgo Pharma, Cardero Therapeutics, Milo Biotechnology, PTC Therapeutics, ReveraGen BioPharma and Sarepta Therapeutics.
DMD is a condition which causes muscle weakness, and is an X-linked disorder. The gene for DMD is present on the X chromosome. It codes for a protein named dystrophin. Dystrophin is essential for providing structural support inside muscle cells. Symptoms usually appear before age 6 and may appear as early as infancy. They include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.
Any questions? Feel free to reach us at https://www.marketinsightsreports.com/reports/051811077/genetic-disorder-cluster-muscular-dystrophy-drug-development-pipeline-review-2017/inquiry
There is a far larger pipeline for DMD than for BMD; there are a total of 108 products in development for DMD, by 57 companies and nine academic institutions. Key companies operating in this pipeline space include Sarepta Therapeutics, PTC Therapeutics, WAVE Life Sciences, Solid Biosciences, Summit Therapeutics and Catabasis Pharmaceuticals. Of particular importance are Sarepta, who are developing twelve distinct pipeline products for DMD. As with BMD, these are all smaller enterprises, although there is some involvement from larger pharmaceutical companies such as Pfizer and Merck in the DMD pipeline.
The majority of pipeline products for DMD target dystrophin which, as mentioned, is the causative gene for the disease. However, a number of products act on other molecular targets such as growth differentiation factor 8, nuclear factor kappa B and utrophin. The first two of these make up the pipeline for BMD, along with forkhead box protein 1B.
Scope of this research: Which companies are the most active within the pipeline for genetic disorder therapeutics? Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? What are the most important R&D milestones and data publications to have happened in the field of genetic disorder therapeutics?
This research will help you to:-
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration